Meanwhile, our study validated above result by analyzing 414 DLBCL patients with univariate analysis and multivariate analysis, which demonstrated that gender was associated with poor prognosis (HR = 1.01) of DLBCL patients treated with CHOP/R‐CHOP, although they did not reach the significant level (P = 0.954 and P = 0.929, respectively). This evidence concerns the gene DDIT3 and diffuse large B-cell lymphoma.